Bone Is a Target for the Antidiabetic Compound Rosiglitazone

Endocrinology

Volumn 145, Issue 1, 2004, Pages 401-406

  Rzonca, S O ^a   Suva, L J ^b   Gaddy, D ^b   Montague, D C ^b   Lecka Czernik, B ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; FATTY ACID BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BONE METABOLISM; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOARCHITECTURE; DIABETES MELLITUS; DRUG EFFECT; EXTRACELLULAR MATRIX; GLUCONEOGENESIS; INSULIN SENSITIVITY; MALE; MARKER GENE; MESENCHYME CELL; MOUSE; NONHUMAN; OSTEOBLAST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN TARGETING; TRABECULAR BONE;

ANIMALS; BONE DENSITY; BONE MARROW; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLIDINEDIONES; TIBIA; TRANSCRIPTION FACTORS;

EID: 0347719481     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2003-0746     Document Type: Article

References (40)

1. Werner AL, Travaglini MT 2001 A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 21:1082-1099
2. Henney JE 1999 From the Food and Drug Administration. JAMA 282:932
3. Kahn CR, Chen L, Cohen SE 2000 Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 106:1305-1307
4. Li AC, Brown KK, Silvestre MJ, Wilson TM, Palinski W, Glass CK 2000 Peroxisome proliferator-activated receptor y ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106:523-531
5. Girnun GD, Spiegelman BM 2003 PPAR-γ ligands: taking part in chemo-prevention. Gastroenterology 124:564-567
6. Kersten S, Desvergne B, Wahli W 2000 Roles of PPARs in health and disease. Nature 405:421-424
7. Landreth GE, Heneka MT 2001 Anti-inflammatory actions of peroxisome proliferator-activated receptor-γ agonists in Alzheimer's disease. Neurobiol Aging 22:937-944
8. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA 1995 An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor-γ (PPAR-γ). J Biol Chem 270:12953-12956
9. Lee CH, Olson P, Evans RM 2003 Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144: 2201-2207
10. Rosen ED, Spiegelman BM 2001 PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276:37731-37734
11. Zhu Y, Qi C, Korenberg JR, Chen X, Noya D, Rao MS, Reddy JK 1995 Structural organization of mouse peroxisome proliferator-activated receptor-γ (mPPAR-γ) gene: alternative promoter use and different splicing yield two mPPAR-γ isoforms. Proc Natl Acad Sci USA 92:7921-7925
12. Ren D, Collingwood TN, Rebar EJ, Wolffe AP, Camp HS 2002 PPARγ knockdown by engineered transcription factors: exogenous PPARγ2 but not PPAR-γ1 reactivates adipogenesis. Genes Dev 16:27-32
13. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM 2002 Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418:41-49
14. Bianco P, Riminucci M, Gronthos S, Robey PG 2001 Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 19:180-192
15. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Rao Y-H, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T 1997 Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755-764
16. Acampora D, Merlo GR, Paleari L, Zerega B, Postiglione MP, Mantero S, Bober E, Barbieri O, Simeone A, Levi G 1999 Craniofacial, vestibular and bone defects in mice lacking the Distal-less-related gene Dlx5. Development 126: 3795-3809
17. Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC, Jilka RL 1999 Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPAR-γ2. J Cell Biochem 74:357-371
18. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL 2002 Divergent effects of selective peroxisome proliferator-activated receptor-γ2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143:2376-2384
19. Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriquez BR, Kliewer SA, Lehmann JM, Morris DC 1996 Peroxisome proliferator-activated receptor-γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 50:1087-1094
20. Schwartz AV, Sellmeyer DE, Feingold KR, Strotmeyer E, Resnick HE, Carbone L, Beamer BA, Lane NE, Cummings SR 2002 Thiazolidinedione (TZD) use and bone density in older adults with diabetes. Diabetes 51:A237 (Abstract)
21. Samuels A, Perry MJ, Gibson R, Tobias JH 2001 Effects of combination therapy with PTH and 17β-estradiol on long bones of female mice. Calcif Tissue Int 69:164-170
22. Iida-Klein A, Lu SS, Yokoyama K, Dempster DW, Nieves JW, Lindsay R 2003 Precision, accuracy, and reproducibility of dual x-ray absorptiometry measurements in mice in vivo. J Clin Densitom 6:25-33
23. Hildebrand T, Ruegsegger P 1997 Quantification of bone microarchitecture with the structure model index. Comput Methods Biomech Biomed Engin 1:15-23
24. Amblard D, Lafage-Proust MH, Laib A, Thierry T, Ruegsegger P, Alexandre C, Vico L 2003 Tail suspension induces bone loss in skeletally mature mice in the C57BL/6J strain but not in the C3H/HeJ strain. J Bone Miner Res 18: 561-569
25. Suva LJ, Seedor JG, Endo N, Quartuccio HA, Thompson DD, Bab I, Rodan GA 1993 Pattern of gene expression following rat tibial marrow ablation. J Bone Miner Res 8:379-388
26. Jilka RL, Weinstein RS, Takahashi K, Parfitt AM, Manolagas SC 1996 Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J Clin Invest 97:1732-1740
27. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphomerry Nomenclature Committee. J Bone Miner Res 2:595-610
28. Bustin SA 2000 Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 25:169-193
29. Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, Tanaka H, Lazar MA 1998 A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor-γ-activating properties. J Biol Chem 273:32679-32684
30. Chao L, Marcus-Samuels B, Mason MM, Moitra J, Vinson C, Arioglu E, Gavrilova O, Reitman ML 2000 Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 106: 1221-1228
31. Matsusue K, Haluzik M, Lambert G, Yim S-H, Gavrilova O, Ward JM, Brewer Jr B, Reitman ML, Gonzalez FJ 2003 Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest 111:737-747
32. Yu S, Matsusue K, Kashireddy P, Cao W-Q, Yeldandi V Yeldandi AV, Rao MS, Gonzalez FJ, Reddy JK 2003 Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor γ1 (PPARγ1) overexpression. J Biol Chem 278:498-505
33. Bedoucha M, Atzpodien E, Boelsterli UA 2001 Diabetic KKAy mice exhibit increased hepatic PPARγ1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 35:17-23
34. Kaku K, Fiedorek Jr FT, Province M, Permutt MA 1988 Genetic analysis of glucose tolerance in inbred mouse strains. Evidence for polygenic control. Diabetes 37:707-713
35. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN 1988 Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37:1163-1167
36. Tai TAC, Jennermann C, Brown KK, Oliver BB, MacGinnitie MA, Wilkison WO, Brown HR, Lehmann JM, Kliewer SA, Morris DC, Graves RA 1996 Activation of the nuclear receptor peroxisome proliferator-activated receptor gamma promotes brown adipocyte differentiation. J Biol Chem 271:29909-29914
37. Beresford JN, Bennett JH, Devlin C, Leboy PS, Owen ME 1992 Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures. J Cell Sci 102:341-351
38. Nuttall ME, Patton AJ, Olivera DL, Nadeau DP, Gowen M 1998 Human rrabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders. J Bone Miner Res 13:371-382
39. Nuttall ME, Gimble JM 2000 Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis? Bone 27:177-184
40. Tornvig L, Mosekilde LI, Justesen J, Falk E, Kassem M 2001 Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int 69:46-50